Inhibrx plans to test OX40 agonist with cancer vaccines in less immunogenic tumors
Inhibrx Biosciences reported mid-stage results suggesting its OX40 agonist works in immunogenic cancers. The company now intends to launch combination studies with cancer vaccines starting early next year, targeting tumors that are less immunogenic.
Recent mid-stage clinical findings from Inhibrx Biosciences indicate that its OX40 agonist demonstrates activity in cancers that naturally elicit a robust immune response. This positive signal validates the drug's mechanism in highly reactive tumor environments.
Building on this momentum, the company is pivoting its research strategy. Starting early next year, it will initiate combination trials pairing the agonist with cancer vaccines, specifically aiming to boost immune recognition in tumor types that currently evade effective immune surveillance.
If these combination studies succeed, they could significantly expand the patient population eligible for immunotherapy, offering potential new options for those with traditionally resistant cancers. This may lead to improved outcomes for individuals facing difficult diagnoses, though the early-stage nature of the research means any clinical impact remains uncertain and will require rigorous validation in larger trials.